Next Article in Journal
Clinical Manifestations in a Girl with NAA10-Related Syndrome and Genotype–Phenotype Correlation in Females
Next Article in Special Issue
The Importance of Being PI3K in the RAS Signaling Network
Previous Article in Journal
A Literature-Derived Knowledge Graph Augments the Interpretation of Single Cell RNA-seq Datasets
Previous Article in Special Issue
The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction
Review

Drugging the Undruggable: Advances on RAS Targeting in Cancer

1
Oncogene Biology Laboratory, Francis Crick Institute, London NW1 1AT, UK
2
Department of Medical Oncology, Imperial College Healthcare NHS Trust, London W2 1NY, UK
3
Lung Cancer Group, Institute of Cancer Research, London SW3 6JB, UK
*
Authors to whom correspondence should be addressed.
Academic Editor: Esther Castellano-Sánchez
Received: 20 May 2021 / Revised: 2 June 2021 / Accepted: 4 June 2021 / Published: 10 June 2021
(This article belongs to the Special Issue RAS Signaling in Health and Disease)
Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective therapies despite decades of research. Recently, characterisation of the biochemical properties of KRAS-G12C along with discovery of its ‘switch-II pocket’ have allowed development of effective mutant-specific inhibitors. Currently seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we discuss historical efforts to target RAS directly and approaches to target RAS effector signalling, including combinations that overcome limitations of single-agent targeting. We also review pre-clinical and clinical evidence for the efficacy of KRAS-G12C inhibitor monotherapy followed by an illustration of combination therapies designed to overcome primary resistance and extend durability of response. Finally, we briefly discuss novel approaches to targeting non-G12C mutant isoforms. View Full-Text
Keywords: RAS; KRAS-G12C; oncogene; cancer; targeted therapy RAS; KRAS-G12C; oncogene; cancer; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Molina-Arcas, M.; Samani, A.; Downward, J. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes 2021, 12, 899. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12060899

AMA Style

Molina-Arcas M, Samani A, Downward J. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes. 2021; 12(6):899. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12060899

Chicago/Turabian Style

Molina-Arcas, Miriam, Amit Samani, and Julian Downward. 2021. "Drugging the Undruggable: Advances on RAS Targeting in Cancer" Genes 12, no. 6: 899. https://0-doi-org.brum.beds.ac.uk/10.3390/genes12060899

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop